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COMPOSITIONS COMPRISING CITRATE
AND APPLICATIONS THEREOF
CROSS REFERENCE TO RELATED
APPLICATION
This application claims priority pursuant to 35 U.S.C.
§119(e) to U.S. Provisional Patent Application Ser. No.
61/748,906,filed on Jan. 4, 2013, which is hereby incorpo-
rated by reference in its entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
This invention was made with government support under
grant 0954109 awarded by the National Science Foundation
(NSF) and grant EB012575 awarded by the National Insti-
tutes of Health (NIH). The governmenthascertain rights in
the invention.
FIELD
This invention relates to citrate-presenting compositions
and, in particular, to citrate-presenting compositions for
bone applications.
BACKGROUND
The native bone matrix is a composite comprising about
60 to 65% by weight of inorganic materials embedded
within a collagen protein matrix. In addition, a thin layer of
apatite nanocyrstals is embedded within the collagen net-
work. Some engineered biomaterials have therefore com-
bined various inorganic materials with synthetic polymers
for use in bone tissue engineering applications. However,
some existing biomaterials fail to match the native compo-
sition of bone, provide adequate mechanical support, mini-
mize inflammatory responses, quickly promote bone regen-
eration, and/or fully integrate with surroundingtissue.
Therefore, there exists a need for compositions and meth-
ods that provide improvedproperties for various orthopedic
and boneapplications, including improved mechanical prop-
erties and/or improved bone growth properties.
SUMMARY
In one aspect, compositions are described herein which, in
some cases, can provide one or more advantages compared
to other compositions for bone applications. For example, in
some embodiments, a composition described herein can
provide improved mechanical properties, reduced inflam-
matory responses, improved biodegradability, and superior
integration with surrounding tissue. Further, in some cases,
a composition described herein can promote bone growth in
an improved manner, including by promoting cell differen-
tiation or phenotype progression in a population of bone
cells such as a population comprising stem cells or osteo-
blast cells. In addition, in some instances, a composition
described herein can also inhibit the growth of cancer,
including bone cancer.
Acomposition described herein, in some embodiments,is
a citrate-presenting composition. For example, in some
cases, a citrate-presenting composition described herein
comprises a polymer or oligomer comprising a citrate moi-
ety. In some embodiments, a composition described herein
comprises afirstpolymeror oligomerhavingthe structure of
Formula (1) described hereinbelow and a second polymer or
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oligomer having the structure of Formula (II) described
hereinbelow, wherein the first polymer or oligomer is
blended with the second polymer or oligomer. Further, in
some cases, the first polymer or oligomer and the second
polymer or oligomer are cross linked with one another to
form a polymer network. Additionally, in some instances,
the composition further comprises a particulate material
dispersed in the polymer network. The particulate material
can be one or more of hydroxyapatite, tricalcium phosphate,
biphasic calctum phosphate, bioglass, ceramic, magnesium
powder, magnesium alloy, and decellularized bone tissue
particles.
Moreover, in some embodiments, a composition
described herein further comprises bone tissue adhered to
the polymer network. In some cases, the bone tissue sur-
rounds the polymer network and the polymer network is
integrated into the bonetissue.
In another aspect, methods of promoting bone growth are
described herein which, in some instances, can provide one
or more advantages over other methods. In some cases, for
example, a method described herein promotes cell differen-
tiation or phenotype progression in a population of bone
cells, the method comprising providing a citrate-presenting
composition to the bone cells. In some embodiments, the
citrate-presenting composition is provided to the bonecells
at a first stage of cell development selected to obtain first
cell differentiation or phenotype progression. Additionally,
in some cases, a second citrate-presenting composition is
further provided to the bone cells at a second stage ofcell
developmentselected to obtain a second cell differentiation
or phenotype progression. Bone cells treated in accordance
with a method described herein can be in vitro or in vivo. In
some cases, the bone cells comprise bone stem cells. In
addition, in some embodiments, a method of promoting
bone growth described herein comprises disposing a citrate-
presenting composition in a biological environment. Further,
in some embodiments, promoting bone growth comprises
up-regulating osterix (OSX) gene expression and/or alkaline
phosphatase (ALP) gene expression in the biological envi-
ronment. In some instances, promoting bone growth com-
prises improving osteoconductivity and/or osteoinductivity
in the biological environment. In some embodiments, pro-
moting bone growth comprises promoting mineralization or
calcium deposit formation in the biological environment.
Further, in some cases, a method described herein is also
effective for at least partially inhibiting the growth and/or
proliferation of cancer cells, including bone cancer cells.
Moreover, in some embodiments, one or more of the fore-
going effects are provided by a citrate-presenting composi-
tion in a dose-dependent manner.
A citrate-presenting composition provided to bone cells
and/or disposed in a biological environment according to a
method described herein can comprise any composition
described hereinabove. For example, in some embodiments,
the citrate-presenting composition comprises a polymer or
oligomer comprising a citrate moiety, such as a polymer or
oligomerhaving the structure of Formula (1) or Formula(II).
Other polymers or oligomers may also be used. Moreover,
in some such embodiments, a method described herein
further comprises releasing citrate from the polymer or
oligomer by degrading the polymer or oligomer. In other
instances, the citrate-presenting composition comprises cit-
ric acid or aqueous citrate. In some embodiments, the
citrate-presenting composition comprises culture medium
supplemented with citric acid or citrate. Further, in some
cases, a citrate-presenting composition used in a method
described herein provides a citrate concentration between
US 9,492,477 B2
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about 20 uM and about 2000 uM,based on the volumeofthe
composition. Additionally, in some instances, a method
described herein further comprises providing a biological
factor such as BMP-2 to the bonecells.
In yet another aspect, articles comprising citrate-present-
ing compositions are described herein. In some embodi-
ments, an article comprises a citrate-presenting composition
described hereinabove, such as a cross linked polymer
network formed from a polymer or oligomer having the
structure of Formula (J) and/or a polymer or oligomer
having the structure of Formula (II). Moreover, in some
cases, an article described herein forms a biological or
surgical implant such as an orthopedic fixation device such
as a bone screw.
These and other embodimentsare described in more detail
in the detailed description which follows.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 illustrates a scheme for forming a composite
network according to one embodimentdescribed herein.
FIG. 2 illustrates a series of differential scanning calo-
rimetry (DSC) thermograms for a series of compositions
according to some embodiments described herein.
FIG.3A illustrates the compressive modulus ofa series of
compositions according to some embodiments described
herein.
FIG. 3B illustrates the compressive peak strength of a
series of compositions according to some embodiments
described herein.
FIG.4 illustrates the in vitro degradation rate of a series
of compositions according to some embodiments described
herein.
FIG. 5 illustrates scanning electron microscopy (SEM)
images of the mineralization of a series of composites
according to some embodiments of methods described
herein.
FIG.6Aillustrates optical microscope images of calcium
nodule formation according to some embodiments of meth-
ods described herein.
FIG.6B illustrates calcium nodule formation data accord-
ing to some embodiments of methods described herein.
FIG.6C illustrates calcium nodule formation data accord-
ing to some embodiments of methods described herein.
FIG.7 illustrates the expression of alkaline phosphatase
(ALP) according to some embodiments of methods
described herein.
FIG.8Aillustrates the expression ALP according to some
embodiments of methods described herein.
FIG. 8B illustrates the expression of ALP according to
some embodiments of methods described herein.
FIG.9 illustrates osteopontin (OPN) expression according
to some embodiments of methods described herein.
FIG. 10 illustrates optical microscope images of the
results of a method of promoting bone growth according to
some embodiments described herein.
FIG. 11A illustrates SEM images of the results of a
method of promoting bone growth according to some
embodiments described herein.
FIG. 11B illustrates the expression of ALP according to
some embodiments of methods described herein.
FIG. 11C illustrates the expression of osterix (OSX)
according to some embodiments of methods described
herein.
FIG. 12A illustrates a micro-CT imageofthe results of a
method ofpromoting bone growth according to one embodi-
ment described herein.
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FIG. 12B illustrates a micro-CT image ofthe results of a
method ofpromoting bone growth according to one embodi-
ment described herein.
FIG.13 illustrates two micro-CT imagesofthe results of
a method of promoting bone growth according to one
embodiment described herein.
FIG.14 illustrates cell proliferation data corresponding to
one embodiment of a method described herein.
FIG. 15 illustrates cell proliferation data corresponding to
one embodiment of a method described herein.
FIG.16 illustrates cell proliferation data corresponding to
one embodiment of a method described herein.
DETAILED DESCRIPTION
Embodiments described herein can be understood more
readily by reference to the following detailed description,
examples, and figures. Elements, apparatus, and methods
described herein, however, are not limited to the specific
embodiments presented in the detailed description,
examples, and figures. It should be recognized that these
embodiments are merely illustrative of the principles of the
present invention. Numerous modifications and adaptations
will be readily apparent to those of skill in the art without
departing from the spirit and scope of the invention.
In addition, all ranges disclosed herein are to be under-
stood to encompassany andall subranges subsumedtherein.
For example, a stated range of “1.0 to 10.0” should be
considered to include any andall subranges beginning with
a minimum value of 1.0 or more and ending with a maxi-
mum value of 10.0 orless, e.g., 1.0 to 5.3, or 4.7 to 10.0, or
3.6 to 7.9.
All ranges disclosed herein are also to be considered to
include the end points of the range, unless expressly stated
otherwise. For example, a range of “between 5 and 10”
should generally be considered to include the end points 5
and 10.
Further, when the phrase “up to” is used in connection
with an amount or quantity, it is to be understood that the
amount is at least a detectable amount or quantity. For
example, a material present in an amount “up to” a specified
amount can be present from a detectable amount and up to
and including the specified amount.
I. Compositions Comprising Citrate
In one aspect, compositions comprising citrate or present-
ing citrate are described herein. In some embodiments, a
composition comprises a polymeror oligomer comprising a
citrate moiety. A “citrate moiety,” for reference purposes
herein, comprises a moiety having the structure of Formula
(ID):
ain
OR4
R,OOC COORs,
COOR
wherein R,, R;, and R, are independently —H, —CH,,
—CH,.CH,, M*, or a point of attachmentto the remainder of
the polymeror oligomer;
R, is —H or a point of attachment to the remainder of the
polymeror oligomer; and
M*is a cation such as Na* or K*, provided that at least one
of R,, R,, R3, and R, is a point of attachment to the
remainder of the polymer or oligomer.
US 9,492,477 B2
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Any polymeror oligomernot inconsistent with the objec-
tives of the present invention may be used. For example, in
some cases, a polymer or oligomer of a composition
described herein comprises the reaction product of (1) citric
acid, a citrate, or an esterof citric acid such astriethylcitrate
with (11) a polyol such as a diol. Non-limiting examples of
polyols suitable for use in some embodiments described
herein include C2-C20 a,j-n-alkane diols or C2-C20 a,w-
alkene diols. In other instances, a polymer or oligomer of a
composition described herein comprises the reaction prod-
uct of (4) citric acid, a citrate, or an ester of citric acid with
(1) a polyol, and (iii) an amine, an amide, or an isocyanate.
An amine, in some cases, comprises one or more primary
amines having two to ten carbon atoms. In other cases, an
amine comprises one or more secondary ortertiary amines
having twoto fifteen carbon atoms. An isocyanate, in some
embodiments, comprises a monoisocyanate. In other
instances, an isocyanate comprises a diisocyanate such as an
alkane diisocyanate. In addition, a polymeror oligomerof a
composition described herein can also comprise the reaction
product of (4) citric acid, a citrate, or an ester of citric acid
with (11) a polyol, and (iti) a polycarboxylic acid such as a
dicarboxylic acid or a functional equivalent of a polycar-
boxylic acid, such as a cyclic anhydride or an acid chloride
of a polycarboxylic acid. Moreover, the polycarboxylic acid
or functional equivalent thereof can be saturated or unsatu-
rated. For example, in some instances, the polycarboxylic
acid or functional equivalent thereof comprises maleic acid,
maleic anhydride, fumaric acid, or fumary] chloride. In still
other embodiments, a polymeror oligomer of a composition
described herein comprises the reaction product of (1) citric
acid, a citrate, or an ester of citric acid with (11) a polyol, and
(iii) an amino acid such as an alpha-amino acid. An alpha-
amino acid, in some embodiments, comprises an L-amino
acid, a D-amino acid, or a D,L-amino acid. In somecases,
an alpha-amino acid comprises alanine, arginine, aspara-
gine, aspartic acid, cysteine, glycine, glutamine, glutamic
acid, histidine, isoleucine, leucine, lysine, methionine, pro-
line, phenylalanine, serine, threonine, tyrosine, tryptophan,
valine, or a combination thereof. Further, in someinstances,
an alpha-amino acid comprises an alkyl-substituted alpha-
aminoacid, such as a methyl-substituted amino acid derived
from any of the 22 “standard” or proteinogenic amino acids,
such as methyl serine. Additionally, in some cases, an amino
acid forms a pendant group or side group of the polymer or
oligomer of a composition described herein. Moreover, a
reaction product of monomers described herein, in some
cases, is a condensation reaction product of the monomers.
In some cases, a polymer or oligomer of a composition
described herein is a polymeror oligomer described in U.S.
Pat. Nos. 8,530,611; 8,574,311; or No. 8,613,944.
In addition, in some embodiments, a polymeror oligomer
of a composition described herein is formed from one or
more monomers of Formula (A) and one or more monomers
of Formula (B) or (B'):
(A)OR,
R\OOC COOR;,
COOR3
AVALRs n Rg, and
(B)
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-continued
(B’)
NON7yon
wherein R,, R;, and R, are independently —H, —CH,,
—CH,.CH,, or M*;
R, is —H;
R; is —H, —OH, —OCH,, —OCH,CH,;, —CH;, or
—CH,CH,;
R, is —H, —CH;, or —CH,CH,;
M*is a cation such as Na* or K*; and
n and m are independently integers ranging from 1 to 20.
In some cases, for instance, R,, R., and R, are —H, R, is
—OH,and R, is —H.
In some embodiments, a polymeror oligomer of a com-
position described herein is formed from one or more
monomers of Formula (A), one or more monomers of
Formula (B)or (B'), and one or more monomers of Formula
(C):
>
(A)OR4
R,OOC COOR;,
COOR,
(B)
AWSOl.Rs "Re,
(B’)HO
Nebron, and
OCNYRnico, (C)
wherein R,, R;, and R, are independently —H, —CH,,
—CH,.CH,, or M*;
R, is —H;
R; is —H, —OH, —OCH,, —OCH,CH,;, —CH;, or
—CH,CH,;
R, is —H, —CH,, or —CH,CH,;
M*is a cation such as Na* or K*;
nandm are independently integers ranging from 1 to 20; and
p is an integer ranging from 1 to 10.
For example, in some instances, R,, R5, and R, are —H,or
—CH,CH,, R, is —OH, R, is —H, nis 2 to 6, m is 2 to
8, and p is 2 to 6.
Further, in some embodiments of polymers or oligomers
described herein, a monomerof Formula (B) or (B') can be
replaced by an alcohol that does not have the formula of
Formula (B)or (B'). For example, in some embodiments, an
unsaturated alcohol or an unsaturated polyol can be used.
Moreover, in some embodiments, a monomeror oligomer of
Formula (C) can be at least partially replaced by an amino
acid described herein.
Additionally, a polymer or oligomer of a composition
described herein can have at least one ester bond in the
backbone of the polymer or oligomer. In some cases, a
polymer or oligomer has a plurality of ester bonds in the
backbone of the polymer or oligomer, such as at least three
ester bonds, at least four ester bonds, or at least five ester
bonds. In some embodiments, a polymer or oligomer
described herein has between twoester bonds andfifty ester
bonds in the backbone of the polymer or oligomer.
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A polymeror oligomerdescribed herein can be present in
a composition in any amount not inconsistent with the
objectives of the present invention. In some embodiments,
for instance, a composition described herein comprises up to
about 99 weight percent, up to about 95 weight percent, up
to about 90 weight percent, up to about 80 weight percent,
up to about 70 weight percent, up to about 50 weight
percent, up to about 40 weight percent, or up to about 30
weight percent polymer or oligomer. In some cases, a
8
wherein
R, is —H, —OC(O)NH YUW,, or VU 5s
yVVUW\ represents an additional chain of repeating units
having the structure of Formula (1); and
m, n, p, and q are independently integers ranging from 2 to
20; and
a second polymer or oligomer having the structure of
Formula (I):
qq)oO OR 0, ORg
Oo O ORo,RO O OMe yey SO nue
Oo OR, Oo 0 OR, 0
composition described herein comprises between about 20
and about 99 weight percent, between about 30 and about 95
weight percent, between about 30 and about 90 weight
percent, between about 40 and about 90 weight percent,
between about 40 and about 80 weight percent, between
about 50 and about 95 weight percent, between about 50 and
about 90 weight percent, between about 50 and about 80
weight percent, between about 50 and about 70 weight
percent, between about 60 and about 99 weight percent, or
between about 60 and about 80 weight percent.
Moreover, a composition described herein, in some cases,
can comprise a mixture, blend, or combination of two or
more polymers or oligomers. In some instances, the two or
more polymers or oligomersare citrate-containing polymers
or oligomers described herein. In other cases, at least one
polymer or oligomer of the mixture, blend, or combination
does not comprise a citrate moiety. For example, in some
cases, a composition described herein comprises a mixture,
blend, or combination of a citrate-containing polymer or
oligomer described herein with a biodegradable polymer
such as a polyester. In some embodiments, a composition
described herein comprises a mixture, blend, or combination
of a citrate-containing polymeror oligomer described herein
with a poly(actic acid), a poly(methylmethacrylate), a poly
(methacrylate), a poly(acrylic acid), a poly(acrylate), a poly-
carbonate, a polysaccharide such as cellulose, or a combi-
nation thereof.
In some embodiments, a composition described herein
comprises afirstpolymeror oligomerhavingthe structure of
Formula (1):
20
25
30
45
wherein
R, is —H or ww;
ver represents an additional chain of repeating units hav-
ing the structure of Formula (ID); and
m, n, and p are independently integers ranging from 2 to 20,
and
wherein the first polymer or oligomer is blended with the
second polymer or oligomer.
The polymers or oligomers of a mixture, blend, or com-
bination described herein can be present in the mixture,
blend, or combination in any amount not inconsistent with
the objectives of the present invention. In some cases, the
weight ratio of a first polymer or oligomer of a mixture,
blend, or combination of polymers or oligomers to a second
polymeror oligomer of the mixture, blend, or combination
is between about 99:1 and about 1:99. In some instances, the
weight ratio of the first polymer or oligomer to the second
polymeror oligomeris between about 10:1 and about 1:10,
between about 5:1 and about 1:5, between about 3:1 and
about 1:3, or between about 2:1 and about 1:2. Not intending
to be bound bytheory, it is believed that a composition
comprising a mixture of polymers or oligomers described
herein, in some embodiments, can be used to form a com-
posite comprising higher amounts of particulate materials
than otherwise possible. Again not intending to be bound by
theory, it is further believed that a composition comprising
a mixture of polymers or oligomers described herein can
provide a desired combination of properties provided by the
individual polymersor oligomers. For instance, a polymer or
@O OR, O OR,
H HR,O O oO O oO O N N
O OR; O O OR; O O
O OR, O OR,
RO O oO O oO O
oO OR; O O OR; O
US 9,492,477 B2
9
oligomer of Formula (I) may provide greater mechanical
strength than a polymer or oligomer of Formula (I]), but
fewer hydroxyl or carboxyl groups for interacting with a
particulate material such as hydroxyapatite. Thus, in some
cases, the ratio of differing polymeror oligomers included in
a composition described herein is selected based on a
desired amount of one or more functional groups or moieties
and/or a desired mechanical strength ofthe composition. For
example, in some instances, a composition comprising a
relatively large amount of a polymeror oligomer of Formula
(II), compared to the amount of a polymer or oligomer of
Formula (1), can have a higher amount of carboxyl groups
than a composition comprising a relatively small amount of
a polymer or oligomer of Formula (II).
Moreover, in some embodiments, the polymers or oli-
gomers of a mixture, blend, or combination of polymers or
oligomers described herein can be cross linked with one
another to form a polymer network. Cross linking ofa first
polymeror oligomer with a second polymeror oligomer can
be achieved in any mannernot inconsistent with the objec-
tives of the present invention. For example, in some cases,
cross linking is achieved through intermolecular covalent
bonds such as ester or amide bonds between polymers or
oligomers, including by means of a condensation reaction.
In other instances, cross linking can be achieved through the
coupling of unsaturated moieties in the polymers or oligom-
ers, such as ethyleneically unsaturated moieties of maleic
acid moieties.
In addition, in some embodiments, a composition com-
prising a polymer network can further comprise a particulate
material dispersed in the polymer network. Any particulate
material not inconsistent with the objectives of the present
invention may be used. In some cases, the particulate
material comprises one or more of hydroxyapatite, trical-
cium phosphate, biphasic calcium phosphate, bioglass,
ceramic, magnesium powder, magnesium alloy, and decel-
lularized bone tissue particles. Other particulate materials
may also be used.
In addition, a particulate material described herein can
have any particle size and/or particle shape not inconsistent
with the objectives of the present invention. In some
embodiments, for instance, a particulate material has an
average particle size in at least one dimension of less than
about 1000 um,less than about 800 tum, less than about 500
um, less than about 300 um, less than about 100 um, less
than about 50 um, less than about 30 um orless than about
10 um.In some cases, a particulate material has an average
particle size in at least one dimension of less than about 1
um, less than about 500 nm, less than about 300 nm, less
than about 100 nm,less than about 50 nm,orless than about
30 nm. In some instances, a particulate material has an
average particle size recited herein in two dimensions or
three dimensions. Moreover, a particulate material can be
formed of substantially spherical particles, plate-like par-
ticles, needle-like particles, or a combination thereof. Par-
ticulate materials having other shapes may also be used.
A particulate material can be present in a composition
described herein in any amount not inconsistent with the
objectives of the present invention. For example, in some
cases, a composition comprises up to about 70 weight
percent, up to about 60 weight percent, up to about 50
weight percent, up to about 40 weight percent, or up to about
30 weight percent particulate material, based on the total
weight of the composition. In some instances, a composition
comprises between about 1 and about 70 weight percent,
between about 10 and about 70 weight percent, between
about 15 and about 60 weight percent, between about 25 and
40
45
55
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about 65 weight percent, between about 25 and about 50
weight percent, between about 30 and about 70 weight
percent, between about 30 and about 50 weight percent,
between about 40 and about 70 weight percent, or between
about 50 and about 70 weight percent, based on the total
weight of the composition. For example, in some cases, a
composition comprising a polymer network described
herein comprises up to about 65 weight percent hydroxy-
apatite. Not intending to be bound bytheory, it is believed
that the incorporation of up to about 65 weight percent
hydroxyapatite in a polymer network described herein can
enhance the osteoconductivity and/or osteointegration pro-
vided by the polymer network in a biological environment or
in vitro.
Further, a particulate material described herein can be
dispersed in a polymer network in any manner not incon-
sistent with the objectives of the present invention. In some
embodiments, for instance, the particulate material is mixed
or ground into the polymer network. In addition, a particu-
late material described herein, in some cases, can be che-
lated or otherwise bound by one or more pendant functional
groups of the polymer network.For instance, in some cases,
a composition comprises hydroxyapatite particles dispersed
in a polymer network described herein, wherein the
hydroxyapatite is chelated by one or more pendant func-
tional groups of the polymer network. In some embodi-
ments, one or more carboxyl moieties or one or morecitrate
moieties of the polymer network chelate one or more
calcium-containing portions of the hydroxyapatite. Not
intending to be bound by theory, it is believed that such
chelation can permit the incorporation of larger amounts of
hydroxyapatite (or another inorganic material) within a
polymer network described herein, compared to some other
polymer matrices.
A polymeror oligomeror cross linked polymer network
of a composition described herein, in some embodiments,
can exhibit one or more desirable properties for biomedical
or tissue engineering applications. For example, in some
cases, a polymer or oligomer or a cross linked polymer
network of a composition described herein is biodegradable.
A “biodegradable” polymer or oligomer or cross linked
polymernetwork, for reference purposes herein, degrades in
vivo to non-toxic components which can be cleared from the
body by ordinary biological processes. In some embodi-
ments, a biodegradable polymeror oligomeror cross linked
polymer network described herein completely or substan-
tially completely degrades in vivo over the course of about
4 weeksor less. Further, in some embodiments, a polymer
or oligomer or cross linked polymer network described
herein is biocompatible or cytocompatible. A “biocompat-
ible or cytocompatible” polymer or oligomerorcross linked
polymernetwork, for reference purposes herein, is non-toxic
and does not cause substantial tissue inflammation, where
inflammation can be measured by the amount of fibrocap-
sule formation.
In addition, in some embodiments, a polymeror oligomer
or cross linked polymer network of a composition described
herein exhibits high mechanical strength. In some cases, for
instance, a polymer or oligomer or cross linked polymer
network of a composition described herein exhibits one or
more properties described in Table I below, when measured
as described hereinbelow in Example 2.
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TABLE I
 
Mechanical Properties.
 
Compressive Modulus Peak Load Peak Stress(MPa) (N) (MPa)
>2000 >2000 >70
>2300 >2300 >90
>3000 >2500 >100
1500-4000 1500-4000 70-130
1800-3800 2000-3500 70-120
2300-3600 2300-3300 85-120
2500-3500 2500-3100 90-120
Moreover, in some embodiments, a composition
described herein can further comprise bonetissue. Any bone
tissue not inconsistent with the objectives of the present
invention may be used. In some embodiments, for instance,
the bone tissue comprises compact bone tissue. In other
cases, the bone tissue comprises spongy bonetissue. Further,
in some embodiments, the bone tissue is adhered to a
polymer network of the composition, including a polymer
network described herein. Additionally, in some instances,
the bone tissue surrounds the polymer network and the
polymer network is integrated into the bone tissue. Such a
composition, in some cases, can exhibit a high bone-to-
implant contact (BIC), where the “bone”refers to the bone
tissue and the “implant” refers to the polymer network. In
some embodiments, a composition described herein exhibits
a bone-to-implant contact of at least about 70 percent, at
least about 80 percent, at least about 90 percent, at least
about 95 percent, or at least about 99 percent, when mea-
sured as described herein. In some embodiments, a compo-
sition described herein exhibits a bone-to-implant contact
between about 70 and about 99 percent, between about 75
and about 95 percent, between about 80 and about 95
percent, or between about 80 and about 90 percent, when
measured as described herein. Further, in some cases, a
composition described herein exhibits no fibrous tissue
encapsulation or substantially no fibrous tissue encapsula-
tion after six weeks in vivo. “Substantially no fibrous tissue
encapsulation,” for reference purposes herein, means that
less than about 5 weight percent or less than about 1 weight
percent of the composition encapsulates fibrous tissue.
It is to be understood that a composition described herein
can have any combination ofproperties or features described
herein not inconsistent with the objectives of the present
invention. For example, any polymeror oligomer described
herein can be used in combination with any amountor type
of particulate material described herein. In some embodi-
ments, for instance, a composition can comprise a polymer
or oligomer having the structure of Formula (1) and/or
Formula (II), wherein the one or more polymers or oligom-
ers are cross linked to form a polymer network and a
particulate material comprising hydroxyapatite is dispersed
within the polymer network. Other combinations are also
possible.
II. Methods of Promoting Bone Growth
In another aspect, methods of promoting bone growth are
described herein. In some embodiments, a method of pro-
moting bone growth comprises providing a citrate-present-
ing composition to a population of bone cells. Further, in
some cases, promoting bone growth comprises promoting
cell differentiation and/or phenotype progression in the
population of bone cells. For example, in some instances,
providing a citrate-presenting composition to a population of
bonecells promotes osteoblast phenotype progression in the
population of bone cells. Further, in some such embodi-
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ments, the citrate-presenting composition is provided to the
bone cells at a first stage of cell development selected to
obtain a first cell differentiation or phenotype progression.
Additionally, in some cases, a second citrate-presenting
composition can be further provided to the bone cells at a
second stage of cell development selected to obtain a second
cell differentiation or phenotype progression. In other
embodiments, a method of promoting bone growth
described herein comprises disposing a citrate-presenting
composition in a biological environment. A “biological
environment,” for reference purposes herein, comprises an
environmentwithin a living organism, such as a bonesite or
a wound or injury site. In some cases, promoting bone
growth comprises up-regulating osterix gene expression
and/or alkaline phosphatase gene expression in the biologi-
cal environment. Additionally, a method of promoting bone
growth described herein, in some embodiments, further
comprises releasing free citric acid or citrate from the
citrate-presenting composition.
Turning now to steps of methods, methods of promoting
bone growth described herein comprise providing a citrate-
presenting composition to a population of bonecells and/or
disposing a citrate-presenting composition in a biological
environment. A “citrate-presenting composition,” for refer-
ence purposes herein, is a composition that includes citric
acid, a citrate, an ester of citric acid such astriethyl citrate,
or a chemical species comprising a moiety having the
structure of Formula (IV):
dv)ORy
R\OOC COOR;,
COOR3
wherein R,, R;, and R, are independently —H, —CH,,
—CH,.CH,, M*, or a point of attachmentto the remainder of
the chemical species;
R, is —H or a point of attachment to the remainder of the
chemical species; and
M?*is acation such as Na* or K*. In some embodiments, the
chemical species is a polymer or oligomer. Thus, the
“citrate” of a “citrate-presenting composition” described
herein can refer to a small molecule or “monomeric” form
of citric acid, such as citric acid, a citrate salt, or an ester
of citric acid, as described hereinabove.
Anycitrate-presenting composition not inconsistent with
the objectives of the present invention may be used in a
method described herein. In some embodiments, for
instance, a citrate-presenting composition comprises an
aqueous solution of citric acid and/or a citrate such as
sodium citrate or potassium citrate. In other cases, a citrate-
presenting composition comprises a polymer or oligomer
described hereinabove in Section I or a mixture, blend, or
combination of polymers or oligomers described herein-
above in Section I. For example, in some embodiments, a
citrate-presenting composition comprises a polymeroroli-
gomer comprising a citrate moiety, such as a polymer or
oligomerhaving the structure of Formula (1) or Formula(II).
A citrate-presenting composition of a method described
herein can also comprise a mixture, blend, or combination of
a polymeror oligomer having the structure of Formula (I)
and a polymer or oligomer having the structure of Formula
(II). Other polymers or oligomers may also be used, as
described hereinabove.
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Further, a citrate-presenting composition described herein
can be provided to a population of bonecells in any manner
not inconsistent with the objectives of the present invention.
For example, in somecases, a citrate-presenting composi-
tion is provided to the bone cells in vitro as an aqueous
mixture or solution, including a culture medium supple-
mented with citrate. Any culture medium not inconsistent
with the objectives of the present invention may be used. In
some embodiments, for instance, the culture medium com-
prises Minimum Essential Medium Alpha (aMEM), Eagle’s
minimal essential medium (EMEM), Dulbecco’s modified
Eagle’s medium,fetal bovine serum (FBS), or a mixture of
one or more of the foregoing media. Moreover, in some
cases wherein the citrate-presenting composition comprises
a culture medium supplemented with citrate, the culture
medium is free or substantially free of additional bone
growth factors other than the citrate provided by a citrate-
presenting composition described herein. In some embodi-
ments, the culture medium is free or substantially free of
zinc. A culture medium thatis “substantially free” of addi-
tional bone growth factors or other components, for refer-
ence purposes herein, comprises less than about 10 uM or
less than about 1 uM of additional bone growth factor.
Alternatively, in other cases, a culture medium ofa citrate-
presenting composition described herein further comprises
one or more bone growth factors. For example, in some
cases, a culture medium is an osteogenic medium. In other
instances,a citrate-presenting composition is providedto the
bonecells in vivo as an aqueous mixture or solution or as a
solid implant or device, such as a bone screw or boneplate.
Further, it is to be understood that a citrate-presenting
composition provided to bone cells according to a method
described herein, in some embodiments, can be exogenous
to the bonecells.
In addition, in some methods described herein, one or
more citrate-presenting compositions can be provided to
bonecells at one or more stages ofphenotype progression or
cell differentiation. Citrate-presenting compositions
described herein can be provided to bonecells at any stage
or combination of stages not inconsistent with the objectives
of the present invention. In some cases, for instance, a
citrate-presenting composition is provided to bonecells at or
before a mineralization stage, including after the bonecells
have atleast partially differentiated. Citrate-presenting com-
positions mayalso be provided to bonecells at one or more
other stages of phenotype progression or differentiation. In
addition, the same or a different citrate-presenting compo-
sition described herein can be provided at one or more
stages.
A method of promoting bone growth described herein, in
some embodiments, further comprises releasing free citric
acid or citrate from the citrate-presenting composition.
“Free” citric acid or citrate, for reference purposes herein,
comprises citric acid or citrate that is nto covalently bound
to another species such as a polymeror oligomer described
herein. Citric acid or citrate can be released from a citrate-
presenting composition described herein in any manner not
inconsistent with the objectives of the present invention.
Additionally, the citric acid or citrate can be released into
any desired environment. For example, in somecases,citric
acid or citrate can be released into a biological environment
by degrading a citrate-containing polymeror oligomerdis-
posed in the biological environment. Moreover, a polymer or
oligomer can be degraded in any manner not inconsistent
with the objectives of the present invention. In some
embodiments, degrading a polymer or oligomer comprises
hydrolyzing an ester bond of the polymeror oligomer, such
as an ester bondin the backboneofthe polymeror oligomer.
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In other cases, releasing citric acid or citrate from a citrate-
presenting composition does not require hydrolysis, cleav-
age of chemical bonds, or other degradation of the compo-
sition. For example, in some embodiments comprising the
use of aqueoussolutions ofcitric acid or a citrate, free citric
acid or citrate can be released into a desired environment
simply by providing the citrate-presenting composition to
the environment.
In addition, a citrate-presenting composition of a method
described herein, in some instances, can provide a desired
amount of citrate. In some embodiments, for instance, a
citrate-presenting composition described herein provides a
citrate concentration between about 20 uM and about 2000
uM,based on the volume of the composition. Surprisingly,
it has been discovered that providing an amountofcitrate
between about 20 uM and about 2000 uM can promote bone
growth in a manner described herein while also avoiding or
minimizing other effects that may not be desired, as
described further hereinbelow. Other amounts or concentra-
tions of citrate can also be provided. For example, in some
cases, a citrate-presenting composition described herein
provides a citrate concentration between about 20 uM and
about 200 uM, between about 20 uM and about 150 uM,
between about 100 uM and about 2000 uM, between about
100 uM and about 1500 uM, between about 200 uM and
about 2000 uM,between about 200 uM and about 1500 uM,
between about 300 uM and about 1800 uM, between about
500 uM and about 2000 uM, between about 500 uM and
about 1500 uM,between about 800 uM and about 2000 uM,
between about 800 uM and about 1400 uM, between about
1000 uM and about 2000 LM, or between about 1000 uM
and about 1500 uM. In some embodiments, a citrate-pre-
senting composition described herein provides a citrate
concentration greater than about 800 uM or greater than
about 2000 uM.
Moreover, in some embodiments, a method described
herein provides a biological effect in a dose-dependent
manner, based on the amount of citrate provided. For
example, in some cases, a method described herein com-
prises providing a citrate-presenting composition to a popu-
lation of bone cells to up-regulate ALP and/or OSX gene
expression in the cells in a dose-dependent manner, wherein
the amountofcitrate provided is between about 20 uM and
about 2000 uM.
Further, a citrate-presenting composition described herein
can be provided to any population of bonecells not incon-
sistent with the objectives of the present invention. For
example, in some cases, the bone cells comprise osteoblast
cells. In other cases, the bone cells comprise bone marrow
cells such as bone marrow stromal cells. In some embodi-
ments, the bone cells comprise stem cells. The stem cells, in
some cases, can be adult stem cells. In some instances, the
population of bone cells comprises multipotent, oligopotent,
or unipotent stem cells. In some embodiments,the stell cells
comprise mesenchymal stem cells such as C2C12 cells or
human mesenchymal stem cells (aMSC). Moreover, the
bone cells can be in vitro, in vivo, endogenous, or exog-
enous.
Methods of promoting bone growth described herein, in
some embodiments, further comprise providing a biological
factor to a population ofbone cells. A “biological factor,” for
reference purposes herein, comprises a substance that func-
tions in a specific biochemical pathway or bodily process,
such as a growth factor. Any biological factor not inconsis-
tent with the objectives of the present invention may be
used. For example, in some embodiments, a biological
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factor comprises a bone morphogenetic protein (BMP). A
BMP, in some cases, comprises one or more of BMP-2,
BMP-3, BMP-4, BMP-6, and BMP-7. Other biological
factors may also be used.
Methods of promoting bone growth described herein, in
some embodiments, comprise up-regulating osterix (OSX)
gene expression and/or alkaline phosphatase (ALP) gene
expression. In some instances, up-regulating OSX gene
expression comprises increasing the gene expression by up
to about 300 percent compared to a bare glass control after
48 hours of culture. In some cases, the amount of OSX gene
expression is increased by up to about 200 percent, up to
about 100 percent, up to about 50 percent, or up to about 40
percent. In some embodiments, the amount of OSX gene
expression is increased between about 30 percent and about
300 percent, between about 35 percent and about 250
percent, between about 35 percent and about 200 percent, or
between about 200 percent and about 300 percent, compared
to a bare glass control after 48 hours of culture.
In someinstances, the amount ofALP gene expression is
increased by an amount up to about 400 percent compared
to a bare glass control after 48 hours of culture. In some
cases, the amount ofALP gene expression is increased by up
to about 360 percent, up to about 250 percent, up to about
150 percent, up to about 100 percent, up to about 50 percent,
or up to about 40 percent. In some embodiments, the amount
of ALP gene expression is increased between about 30
percent and about 400 percent, between about 35 percent
and about 360 percent, between about 35 percent and about
300 percent, between about 35 percent and about 250
percent, between about 300 percent and about 400 percent,
or between about 300 percent and about 360 percent, com-
pared to a bare glass control after 48 hours of culture.
Additionally, methods described herein, in some embodi-
ments, comprise providing a citrate-presenting composition
thatat least partially inhibits the growth and/orproliferation
of cancer cells, such as osteosarcoma cells or other bone
cancer cells. In some embodiments, the growth and/or
proliferation of cancer cells is completely inhibited or
arrested, such as when the cancer cells are killed by the
method. In other instances, the growth and/or proliferation
of cancer cells is inhibited by up to about 90 percent, up to
about 80 percent, up to about 70 percent, up to about 50
percent, up to about 30 percent, or up to about 20 percent,
compared to a control method that does not include provid-
ing a citrate-presenting composition to the population of
cells. Moreover, in some embodiments, the effect of a
citrate-presenting composition described herein is dose-
dependent. Further, in some cases, inhibiting the growth
and/or proliferation of cancer cells comprises providing
citrate to the cells at a concentration greater than about 800
uM, such as an amount between about 800 UM and about
20,000 uM or an amount between about 800 uM and about
2000 uM.
Moreover, in some embodiments, methods described
herein comprise providing a citrate-presenting composition
that kills cancer cells such as bone cancer cells. In some
cases,all of the cancercells are killed. In other instances, at
least about 90 percent, at least about 80 percent, at least
about 70 percent, or at least about 50 percent of the cancer
cells are killed, compared to a control method that does not
include providing a citrate-presenting composition to the
population of cells. Additionally, in some embodiments, the
anti-cancer effect of a citrate-presenting composition
described herein is dose-dependent. Further, in some cases,
killing cancer cells comprises providing citrate to the cells at
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a concentration greater than about 2000 uM, such as a
concentration greater than about 2000 uM and up to about
20,000 uM.
It is to be understood that a method of promoting bone
growth described herein can comprise any combination of
steps or use any combination of compositions described
herein not inconsistent with the objectives of the present
invention. In some embodiments, for instance, a method of
promoting bone growth described herein can comprise using
a citrate-presenting composition described hereinabove in
Section I to provide a citrate concentration described here-
inabove to a population of bone cells or to a biological
environmentdescribed hereinabove for the purpose of pro-
moting cell differentiation and/or phenotype progression or
for the purpose of up-regulating osterix gene expression
and/or alkaline phosphatase gene expression.
I. Articles Comprising Citrate-Presenting Compositions
In another aspect, articles comprising citrate-presenting
compositions are described herein. In some embodiments,
an article comprises or is formed from a citrate-presenting
composition described hereinabove in Section I, such as a
cross linked polymer network formed from a polymer or
oligomer having the structure of Formula (1) and/or a
polymeror oligomer having the structure of Formula(II). In
some embodiments, an article described herein comprises or
is formed from a cross linked polymer network described
hereinabove in Section ] comprising a particulate material
dispersed in the polymer network. For example, in some
cases, an article described herein comprises or is formed
from a first polymer or oligomer having the structure of
Formula (1) cross linked with a polymeror oligomer having
the structure of Formula (II) to form a polymer network, the
polymer network further comprising up to about 70 weight
percent hydroxyapatite dispersed throughout the polymer
network.
In some embodiments, an article described herein is a
biological or surgical implant such as an orthopedic fixation
device such as a bone screw or boneplate. Therefore, in
some cases, an article described herein can be used to
promote the healing or mending of bonefractures or other
woundsor injuries by providing mechanical support. More-
over, in some embodiments, an article described herein can
also promote bone growth at the site of a wound or injury
such as a bone fracture. In this manner, an article described
herein can be used to provide improved treatment of bone
fractures, bone growth disorders, and/or bone degeneration
conditions. An article described herein can also inhibit
cancer growth or kill cancer cells in a biological compart-
ment, such as bone.
An article described herein can have any size and shape
not inconsistent with the objectives of the present invention.
In some embodiments, an article described herein has a
cylindrical shape, a spherical shape, or a polyhedral shape.
In other instances, an article described herein has a shape
suitable for use as an orthopedic fixation device, such as a
screw shape or a plate shape.
Further, an article described herein can exhibit one or
more desirable properties, such as one or more desirable
biomedical or mechanical properties. In some instances, for
example, an article described herein exhibits or promotes a
biological effect described hereinabove in Section I or
Section I], such as an increased gene expression effect or an
osteoinductive effect. In other cases, an article described
herein exhibits a compressive modulus described herein-
above in Section I.
In addition, an article described herein can be made in any
manner not inconsistent with the objectives of the present
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invention. For example, in some cases, an article described
herein is made from a composition described herein using an
extrusion process, a pultrusion process, or a molding pro-
cess, including but not limited to an injection molding
process.
Some embodiments described herein are further illus-
trated in the following non-limiting examples. Unless oth-
erwise noted, all experiments described below were con-
ducted in duplicate and repeated three times (n=6), and
statistical results are based on sets of three experiments.
Where appropriate, data is expressed as the meanstone
standard deviation. Thestatistical significance between two
sets of data was calculated using a two-tail Student’s t-test.
Differences were taken to be significant when a value of
P<0.05 was obtained.
EXAMPLE1
POC and CUPE Polymers or Oligomers
Citrate-presenting polymers or oligomers according to
some embodiments described herein were prepared as fol-
lows. A first polymer or oligomer was identified as poly
(octanediol citrate) (POC), and a second polymeror oli-
gomer was identified as cross linked urethane-doped
polyester (CUPE).
To synthesize POC, equimolar amounts of 1,8-octanediol
(98%, Sigma-Aldrich, St. Louis, Mo., USA) andcitric acid
(99.5%, Sigma-Aldrich, St. Louis, Mo., USA) were added to
a 100 mL round bottom flask and exposed to a constant flow
of nitrogen gas. The mixture was melted under vigorous
stirring at 160-165° C. Once the constituents melted, the
mixture was allowed to react at 140° C. for 1 h to create an
unpurified POC polymer or oligomer. Next, the unpurified
polymer or oligomer was added dropwise to deionized
water, collected, and lyophilized overnight to obtain the
purified POC polymer or oligomer.
To synthesize CUPE, a POC polymeror oligomer was
first synthesized by reacting citric acid and 1,8-octanediol in
a 1:1.1 molar ratio, respectively, and further processing the
reaction product as stated above. Next, chain extension of
the POC polymeror oligomer was accomplished by dis-
solving the purified POC polymer or oligomer in 1,4-
dioxane to form a 3 weight percent solution of POC,
followed by reaction with 1,6-hexamethyl diisocyanate
(ADI) (Sigma-Aldrich, St. Louis, Mo., USA) ina 1:1.5 POC
to HDI molar ratio under constant stirring at 55° C. The
reaction was terminated when Fourier transform infrared
(FT-IR) analysis showed a disappearance of the isocyanate
peak at 2267 cm™'.
EXAMPLE2
CBPB Blends and CBPBHA Composites
Polymer networks and polymer networks comprising par-
ticulate material dispersed within the network according to
some embodiments described herein were prepared as fol-
lows. The polymer networks included various blends of a
first polymer or oligomer and a second polymeror oligomer
and were designated as citrate-based polymer blends (CB-
PBs). The polymer networks comprising particulate material
were designated as citrate-based polymer blend/hydroxy-
apatite (CBPBHA) composites. CBPBHA composites were
fabricated in three steps. First, a mixture of CUPE and POC
wasfirst prepared by dissolving a POC polymeror oligomer
in 1,4-dioxane or tetrahydrofuran (THF) and mixing the
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POC solution with various weight ratios of solutions of
CUPEpolymer or oligomer in 1,4-dioxane or THF to form
a homogenous citrate-based polymer or oligomer blend,
designated as CBPB-X, where X is defined as the weight
ratio of CUPE in the CBPB blend. Second, each CBPB was
mixed with 65 weight percent hydroxyapatite (HA, [MW:
502.32; assay: >90% (as Ca,(PO,),); particle size: >75 um
(0.5%), 45-75 wm (1.4%), <45 um (98.1%)], Fluka, St.
Louis, Mo., USA), based on the total weight of the compo-
sition, andstirred in Teflon dishes pre-warmed to 50° C.to
aid in solvent evaporation. Following solvent evaporation,
the clay-like mixture was inserted into machined cylindrical
metal molds and compressed into rod shaped samples.
Finally, the resulting cylindrical composites were post-
polymerized at 80° C. for 5 days followed by heating at 120°
C. under 2 Pa vacuum for 1 day to form a crosslinked
CBPBHA-X composite, where X is again defined as the
weight ratio of CUPE in CBPB.Theresults are shown in
Table II. Composites including particulate materials other
than HA could also be prepared in the same manner. This
processis illustrated schematically in FIG. 1. As depicted in
FIG. 1, CUPE polymeror oligomer backbones are repre-
sented as being disposed essentially vertically, and POC
polymer or oligomer backbones are represented as being
disposed essentially horizontally. However, this depiction is
for illustration purposes only. As understood by one of
ordinary skill in the art, the orientation of the CUPE and
POC backbones can be random. In addition, as depicted in
FIG.1,the larger circles in the composite network represent
HAparticles, the smaller circles represent ester or urethane
linkages, and the dashed lines indicate pendant carboxyl
groups.
TABLEII
 
CBPB Polymer Blends and CBPBHA Composites.
CUPE POC HA
Composition (wt. %) (wt. %) (wt. %)
CBPB-100 100 0 0
CBPB-90 90 10 0
CBPB-50 50 50 0
CBPB-0 0 100 0
CBPBHA-100 100 0 65
CBPBHA-90 90 10 65
CBPBHA-80 80 20 65
CBPBHA-70 70 30 65
CBPBHA-60 60 40 65
CBPBHA-50 50 50 65
CBPBHA-0 0 100 65
 
CBPBblends and CBPBHA composites were character-
ized using differential scanning calorimetry (DSC). Specifi-
cally, measurements were carried out using a DSC Q2000
Differential Scanning Calorimeter (TA Instruments, New
Castle, Del., USA) to characterize the thermal properties and
homogeneity of the CBPB polymer blends (CBPB-100,
CBPB-90, CBPB-50, and CBPB-0). Samples were initially
scanned from room temperature to 150° C. undernitrogen at
a heating rate of 10° C. per min., followed by cooling at a
rate of -40° C. per min. until a temperature of -75° C. was
achieved. Samples were then scanned again from -75° C.to
150° C. at a heating rate of 10° C. per min. The glass
transition temperature (T,,) was determined from the middle
of the recorded step change in heat capacity from the second
heating run. To determine the miscibility of the two poly-
mers or oligomers in a CBPB blend, the glass transition
temperature of the blend was expressed by Equation (2) (the
Fox Equation):
V/T,=W/Tg1+WlTqo (2),
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where W,is the weight fraction of component i and tem-
peratures are in Kelvin. Results are shown in FIG.2. FIG. 2
illustrates DSC thermograms of various CBPB blends. Val-
ues are reported as the meantonestandard deviation, with
n=6. The CBPB blends exhibited a single glass transition
temperature that increased with increasing CUPE content
under the same polymerization conditions (5 days, 80° C.).
The T, values for CBPB-90 and CBPB-50, based on the T,
values of the individual components CBPB-100 and CBPB-
0, were calculated to be 0.41° C. and -9.13° C., respectively.
Unconfined compression tests were performed on the
CBPBHA composites using an Electromechanical Universal
testing machine Q Test-150 (MTS, Eden Prairie, Minn.,
USA). Briefly, cylindrical shaped specimens 6 mmx9 mm
(diameterxheight) were compressed at a rate of 2 mm per
min. to failure. The initial modulus was calculated by
measuring the gradient at 10% of compression ofthe stress-
strain curve. Results are shown in Table II and in FIGS. 3A
and 3B. FIG. 3A illustrates the compressive modulus of
CBPBHA composites. FIG. 3B illustrates the compressive
peak strength of CBPBHA composites. The x-axis values
represent the CUPE percentage in the CBPB blends.
TABLEIII
 
Mechanical Properties.
Compressive Peak Load Peak Stress
Composition Modulus (MPa) (N) (MPa)
CBPBHA-100 =2308.17 + 84.31 2308.71 + 104.47 87.93 + 3.54
CBPBHA-90 3419.29 + 191.97 3077.86 + 159.98 116.23 + 5.37
CBPBHA-80 2415.29 + 118.62 2476.86 + 143.34 90.29 + 5.41
CBPBHA-70 2396.14 + 255.29 2694 + 167.93 97.13 + 6.98
CBPBHA-60 2584.43 + 163.11 2530.14 + 139.43 92.30 + 5.15
CBPBHA-50 2352.43 + 335.83 2334 + 238.75 83.47 + 11.81
CBPBHA-0 2628.43 + 148.14 2353.14 * 156.57 88.63 + 7.17
 
The in vitro degradation rate of disk samples (6 mm
diameterx2 mm thick) of the CBPBHA composites was
assessed by weight loss over time. The samples were dis-
posed in phosphate-buffered saline (PBS) (pH 7.4) at 37° C.
for up to 24 weeks understatic conditions. PBS was changed
every week to ensure that the pH did not drop below 7. Prior
to weighing, samples were extensively rinsed with deionized
(DI) water and lyophilized. Weight loss was calculated by
comparing the initial weight (W,) with the weight measured
at 1, 2, 4, 8, 12, and 24 weeks (W,), as shown in Equation
(1):
Weight Loss=(¥o- W,)/ Wox 100% (1).
Results are shown in FIG. 4 as mean+one standard deviation
(n=6).
In vitro mineralization of CBPBHA composites was
assessed using 4x modified simulated body fluid (SBF)
solution consisting of (mmol): Na* (142.0), K* (5.0), Mg**
(1.5), Ca?* (2.5), Cl (103), HCO, (10.0), HPO,,?- (1.0) and
SO," (0.5) with the pH adjusted to 7.0 using 1.0 M NaOH
for accelerated results. Briefly, composite disks (6 mm
diameterx2 mm height) were immersed in 10 mL ofthe SBF
at 37° C. for up to 15 days. SBF wasrefreshed every other
day to maintain the ionic concentration and pH during
mineralization. After incubation for various periods oftimes,
the specimens were washed carefully with DI water to
removeany soluble inorganic ions anddried in air. Samples
were then coated with silver and observed under a scanning
electron microscope (SEM) (Hitachi, Pleasanton, Calif.,
USA). The stoichiometric Ca/P molar ratio was analyzed by
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energy-dispersive x-ray (EDX) analysis and determined to
be 1.39+0.25. As illustrated in FIG. 5, all of the CBPBHA
composites induced rapid mineralization. The images
labeled A-1, A-2, and A-3 in FIG. 5 correspond to CBP-
BHA-O at 0, 3, and 15 days, respectively. A similar labeling
scheme is used for the other composites in FIG.5.
EXAMPLE3
Methods of Promoting Bone Growth
Methods of promoting bone growth according to some
embodiments described herein were carried out as follows.
Bone marrow stromal cells (BMSCs) derived from 6 week
old male Sprague-Dawley rats were cultured in growth
medium containing Minimum Essential Medium Alpha
(aMEM)supplemented with 10% (V/V) fetal bovine serum
(FBS), 0.25 ug/mL Fungizone, and 1% (V/V) penicillin and
streptomycin in 6-well plates at a density of2x10° cells/well
(Day 0). On Day 3 the growth medium was changed into an
osteogenic medium consisting ofCMEM supplemented with
10% fetal bovine serum, 10-? M dexamethasone, 50 g/mL
ascorbic acid (Sigma), 5 mM 6-glycerol phosphate (Sigma),
0.25 ug/mL Fungizone, 1% penicillin and streptomycin, and
various concentrations of citric acid (0 uM, 2 uM, 20 uM,
200 uM, 1 mM, and 5 mM). After 12 days of osteogenic
induction, the BMSCscultures were stained with Von Kossa
staining and imaged by optical microscopy. The numbers of
calcium nodules per well were counted in the inverted
microscope. Thetotal area of the calctum nodules was also
calculated. Results are shown in FIGS. 6A-6C. FIG. 6A
illustrates microscope images ofVon Kossastaining FIG. 6B
illustrates the number of observed calcium nodules. FIG. 6C
illustrates the total area of the calcium nodules. It was found
that all citrate-supplemented culture media promoted cal-
cium module formation in a dose-dependent manner. A
citrate concentration of 20 uM induced the highest number
of calctum nodules (black in FIG. 6A) with larger sizes,
while the control medium did notfacilitate visible calctum
nodule formation.
EXAMPLE4
Methods of Promoting Bone Growth
Methods of promoting bone growth according to some
embodiments described herein were carried out as follows.
MG-63 cells (ATCC, Manassas, Va., USA) were cultured in
EMEM(Life Technologies, Carlsbad, Calif., USA) supple-
mented with 10% FBS and 1% penicillin and streptomycin.
The MG-63 cells were seeded at 50% confluence in 6-well
plates and cultured with EMEM containing different con-
centrations of citric acid (0 uM, 10 uM, 20 uM, 50 uM, 100
uM, and 200 uM). At 4 days, the cells were lysed and
assayed for the presence of alkaline phosphatase (ALP)
using an ALP substrate kit (Bio-Rad, Hercules, Calif, USA).
The ALPlevels were normalized to the total amount ofDNA
present in the samples as determined by picogreen assay
(Life Technologies, Carlsbad, Calif., USA). Results are
shown in FIG. 7.
In other experiments, MG-63 cells or MSC cells were
cultured and seeded as described above with culture media
containing 0 uM, 20 uM, 100 uM, 200 uM, 1000 uM, or
2000 uM citric acid. The cells were assayed for the presence
ofALPat various time points, such as Day 3, Day 7, Day 10,
Day 14, and Day 21. Results are shown in FIGS. 8A and 8B.
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EXAMPLE5
Methods of Promoting Bone Growth
Methods of promoting bone growth according to some
embodiments described herein were carried out as follows.
Human mesenchymal stem cells (hMSCs) (Lonza Walkers-
ville Inc., USA) were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM)supplemented with 10% FBS and
1% penicillin and streptomycin. For differentiation, hMSCs
were switched to an osteogenic medium (OGM) comprising
the previous DMEM-based medium further supplemented
with 10-7 M £-glycerophosphate and 50 uM ascorbic acid-
2-phosphate. The hMSCcells were seeded at a density of
10* cells/mL after 80-90% confluence in 96-well plates.
After adjusting the pH to 7.4, calculated volumesofcitrate
in the form ofcitric acid were added to the growth medium
to obtain a final citrate concentration of 20 uM, 200 uM,or
2000 uM in the growth medium. The hMSCswere incubated
with the citrate-supplemented media at 37° C. with 5% CO,.
Media were changed every other day. At pre-determined
time points (7 days and 14 days post-addition of citrate), the
osteopontin (OPN)protein levels were determined and com-
pared by Western Blot assay following the manufacturer’s
protocol (Bio-rad Laboratory, USA). Results are shown in
FIG.9. As illustrated in FIG. 9, citrate and OPN expression
were closely associated in a dose-dependentrelationship.
EXAMPLE6
Methods of Promoting Bone Growth
Methods of promoting bone growth according to some
embodiments described herein were carried out as follows.
Human mesenchymal stem cells (hMSCs) (Lonza Walkers-
ville Inc., USA) were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM)supplemented with 10% FBS and
1% penicillin and streptomycin. For differentiation, hMSCs
were switched to an osteogenic medium (OGM) comprising
the previous DMEM-based medium further supplemented
with 10-’ M dexamethasone, 10-? M B-glycerophosphate,
and 50 uM ascorbic acid-2-phosphate. The hMSCcells were
seeded at a density of 10* cells/mL after 80-90% confluence
in 96-well plates. After adjusting the pH to 7.4, calculated
volumesofcitrate in the form ofcitric acid were addedto the
growth medium to obtain a final citrate concentration of 20
uM in the growth medium. The hMSCswere incubated with
the citrate-supplemented medium at 37° C. with 5% CO,.
Media were changed every other day. At pre-determined
time points (7 days, 14 days, and 21 days post-addition of
citrate), the cultures were stained by Von Kossastaining and
then examined by optical microscopeto detect the formation
of calctum deposits. Results are shown in FIG. 10. As
illustrated in FIG. 10, the exogenouscitrate supplement was
able to promote calcium deposit formation in differentiated
hMSCcultures.
EXAMPLE7
Methods of Promoting Bone Growth
Methods of promoting bone growth according to some
embodiments described herein were carried out as follows.
C2C12 cells (ATCC, Manassas, Va., USA) were cultured on
CBPB-100, CBPBHA-100, CBPBHA-90, and control glass
in 24-well plates in high glucose Dulbecco’s modified
Eagle’s medium (GIBCO,Grand Island, N.Y., USA) supple-
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mented with 10% fetal bovine serum, 100 units/mL peni-
cillin, and 100 pg/mL streptomycin at 95% air and 5% CO,.
The total RNA from C2C12 cells was purified using a
RNeasy Mini Kit (QIAGEN,Valencia, Calif, USA). RNA
was subjected to quantitative real-time RT-PCR, using a
TaqMan One-Step RT-PCR Master Mix reagent (Applied
Biosystem, Foster City, Calif, USA). Relative transcript
levels were analyzed by an ABI 7500 real-time PCR system
(Applied Biosystem, Foster City, Calif., USA). Transcript
levels were normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)levels. All experiments were done
in duplicates and repeated three times. Osteoblast differen-
tiation from C2C12 cells was induced by treatment with
BMP-2 (R&D, Minneapolis, Minn., USA). After reaching
60-80% confluency, cells were treated with 300 ng/mL of
BMP-2 for 0, 6, 12, 36, and 48 hours. Osterix (OSX) and
alkaline phosphatase (ALP) gene expression levels were
analyzed as previously described. The morphologies of the
C2C12 cells were visualized using scanning electron
microscopy. Results are shown in FIGS. 11A-C.
After 24 hours, cells formed a monolayer on all CBPBHA
composites investigated (FIG. 11A). In addition, ALP and
OSX gene expression levels on CBPB-100 increased by
35% and 37%, respectively, comparedto a bare glass control
after 48 hours of culture. With incorporation ofHA to CBPB
blends, the ALP and OSX gene expression levels further
increased. ALP and OSX gene expression on the plates
coated with CBPBHA-90 composite increased by 362% and
191%, respectively, and the expression levels on the plates
coated with CBPBHA-100 increased by 336% and 290%,
respectively, comparedto a bare glass control after 48 hours
of culture. When compared to CBPB-100 coated plates after
48 hours, ALP and OSX expression on CBPBHA-90 com-
posites increased by 243% and 113%, respectively, while
ALP and OSX expression on CBPBHA-100 composites
increased by 224% and 185%, respectively (FIGS. 11B and
11C).
EXAMPLE8
Methods of Promoting Bone Growth
Methods of promoting bone growth according to some
embodiments described herein were carried out as follows.
Twelve New Zealand white rabbits weighing between 2.3
and 2.7 kg were used to assess the biocompatibility and
osteointegration properties of CBPBHA-100 and CBPBHA-
90 composites. Cylindrical samples were implanted into the
lateral femoral condyles of rabbit knees. After 6 weeks of
implantation, micro-CT images showedthe complete fusion
of implants and surrounding new bonetissues, as seen in
FIGS. 12A and 12B. FIG. 12A corresponds to CBPBHA-
100, and FIG. 12B corresponds to CBPBHA-90. Additional,
newly formed bone was observedin contact with the implant
in the bone marrow cavity, where originally there was no
bone. Further, there was no evidence of chronic inflamma-
tion (fibrocapsule formation) or degenerative changes
around the implant. On gross histological examination, the
implants appeared well integrated with the surrounding
bone. No implant loosening was detected, as shown in
toluidine staining and von Kossastaining for surrounding
bone tissues. Bone-to-implant contact (BIC) results indi-
cated that the bone-to-implant (osteointegration) was as high
as 94.74%, as seen in FIG. 13. FIG. 13 illustrates 2-D
micro-CT images of the CBPBHA-90 implants with the
surrounding boneofthe lateral femoral condyle at 6 weeks
post-implantation. In addition, there was no bone resorption
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observedat the interface of the undecalcified bone. Further,
there were no positively stained macrophages found at the
interface of implants and surroundingtissues.
All animal experiments were carried out in compliance
with a protocol approved by Southern Medical University’s
Animal Care and Use Committee (Guangzhou, CHINA).
The animals were randomly divided into 2 groups, and
anesthetized by ketamine (40 mg/kg IM)and xylazine (5-7
mg/kg IM) supplemented with isoflurane (1-2% inhalation).
Next, a 1.5 cm medial incision on the lateral knee was
created to expose the lateral femoral condyle. Using a
mosaicplasty harvester (Smith & Nephew, Memphis, Term.,
USA), a 4x3 mm (diameterxdepth) bone defect was drilled
in both the right and left lateral femoral condyles for the
CBPBHA-100 and CBPBHA-90 groups, respectively.
Implants formed from the CBPBHA-100 and CBPBHA-90
composites and matching the dimensions of the defect were
inserted according to the grouping via press fit. After all
surgical procedures, the rabbits were kept in cages and
maintained with a regular laboratory diet. The knees were
harvested at 6 weeks post-implantation and stored in 10%
neutral-buffered formalin. Gross examination was docu-
mented with a digital camera. Computer tomography analy-
sis was conducted using a Micro-CT imaging system
(ZKKS-MCT-Sharp-II] scanner, Caskaisheng, CHINA). The
scanning system was set to 70 kV, 30 W, and 429 LA. The
volume of interest was defined as bone tissue around the
implants, which included the entire trabecular compartment
extending 8 mm from the longitudinal axis of the implant.
The extent of implant osteointegration is generally reflected
by its bone-to-implant contact (BIC) measurement. BIC was
calculated as a percentage of the newly formed bone length
overthe total implant perimeter based on Micro-CT images.
For histological analysis, paraffin-embedded decalcified
tissues were cut into 4 um sections, which were then
deparaffinated, hydrated, and stained with hematoxylin-
eosin (H&E). For immunohistochemical staining, paraflin-
embedded sections were deparaffinated and hydrated
through a gradedseries of alcohol. Endogenous peroxidase
activity was blocked with 0.3% hydrogen peroxide in PBS.
Then the sections were blocked with bovine serum albumin
(1:100 dilution) and incubated with the primary antibody of
CD68 and CD163 (Auragene, Changsha, China, 1:50 dilu-
tion) at 4° C. overnight. The sections were washed with PBS
three times and incubated with secondary anti-mouse IgG
for 1 h at 37° C. The colorization was developed in DAB
solution and counterstained by hematoxylin. The inflamma-
tory reaction surrounding the implant was assessed by two
individual pathologists in a blinded and randomized fashion
from H&Estained sections and JHC staining. The source of
the positive control group was harvested from the healing
tissue of the rat’s Achilles tendon 1 week post-tenotomy,
which has been featured by inflammatory response. IHC
staining was performed for CD163 and CD68 to detect
macrophages. The macrophages appeared brownin the cells
with hematoxylin stained nuclei.
EXAMPLE9
Methods of Inhibiting Cancer Growth
Methods of inhibiting cancer growth according to some
embodiments described herein were carried out as follows.
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First, the effect of citrate on cell proliferation was investi-
gated. Human mesenchymal stem cells (hMSCs) (Lonza
Walkersville Inc., USA) were cultured in growth medium
composed of Dulbecco’s Modified Eagle’s Medium
(DMEM)supplemented with 10% FBS and 1% penicillin/
streptomycin and then seeded in a 96-well plates at a density
of 10* cells/mL after 80-90% confluence. After adjusting the
pHto 7.4, calculated volumesof citrate in the form ofcitric
acid were added to the growth medium to obtain a final
citrate concentration of 20 uM, 200 uM, 400 uM, 800 uM,
1000 uM, 2000 LM, 10,000 uM, or 20,000 uM in the growth
medium. The hMSCs were incubated with the citrate-
supplemented media at 37° C. with 5% CO,. Media were
changed every other day. At pre-determined time points (1
day, 4 days, and 7 days post-addition ofcitrate), the prolif-
eration of the hMSCs was determined by MTT (methylthi-
azolyldiphenyl-tetrazolium bromide) assay following the
manufacturer’s protocol (Sigma, USA). After incubating at
37° C.for 4 hrs in MTT working solution, the hMSCsin the
96-well plates were submerged in dimethylsulfoxide
(DMSO)for 15 minutes on an orbital shaker under dark
conditions. The 96-well plates were then placed on a Micro-
plate Reader to obtain absorbance values at 595 nm. In
addition, live/dead staining was carried out at pre-deter-
mined time points (1 day, 4 days, and 7 days). The hMSCs
were stained with live/dead working solution (Life Tech-
nologies Inc., USA) for 30 minutes and then observed under
a Nikon Inverted Fluorescence Microscopeto determinecell
viability. The results are shown in FIGS. 14 and 15. As
indicated in FIGS. 14 and 15, citrate was found notto affect
hMSCproliferation in the concentration window of20-2000
uM but to suppress hMSCproliferation at higher concen-
trations (above 2000 uM and up to 20,000 uM).
In another experiment, hMSCs and osteosarcomacells
(Saos-2 cells) (ATCC Inc., USA) were cultured in the
presence of citrate. The hMSCs were cultured as described
above. The Saos-2 cells were cultured in McCoy’s 5A
medium (Lonza Walkersville Inc., USA) supplemented with
10% FBSand 1% penicillin/streptomycin. Both hMSCs and
Saos-2 cells were seededin 96-well plates at a density of 10*
cells/mL after 80-90% confluence. After adjusting the pH to
7.4, calculated volumes of citrate in the form ofcitric acid
were added to the growth media to obtain a final citrate
concentration of 20 uM, 200 uM, 400 uM, 800 uM, 1000
uM, 2000 uM, 10,000 uM, or 20,000 uM in the growth
media. The hMSCsand the Saos-2 cells were incubated with
the citrate-supplemented media at 37° C. with 5% CO,.
Media were changed every other day. At pre-determined
time points (1 day and 4 days post-addition ofcitrate), the
proliferations of the hMSCs and Saos-2 cells were deter-
minedas described above. The results are shown in FIGS. 15
and 16. As indicated in FIGS. 15 and 16, citrate was found
to inhibit Saos-2 cell proliferation at concentrations above
800 uM.In addition, at concentrations above 2000 uM, most
Saos-2 cells were killed.
Various embodiments of the present invention have been
described in fulfillment of the various objectives of the
invention. It should be recognized that these embodiments
are merely illustrative of the principles of the present
invention. Numerous modifications and adaptations thereof
will be readily apparent to those skilled in the art without
departing from the spirit and scope of the invention.
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That which is claimedis:
1. A method of promoting bone growth comprising:
(1) providing an amount of a first citrate-presenting
composition to a population of bonecells ata first stage
of cell development selected to obtain a first cell
differentiation or phenotype progression; and
(2) providing an amount of a second citrate-presenting
composition to the population of bonecells at a second
stage of cell development selected to obtain a second
cell differentiation or phenotype progression;
wherein the amount of secondcitrate-presenting compo-
sition provided in step (2) is in addition to the amount
of the first citrate-presenting composition provided in
step (1); wherein the first citrate-presenting composi-
tion comprises a polymer or oligomer comprising a
citrate moiety; and
wherein both the first and secondcitrate-presenting com-
positions are providedto the population of bonecells in
the form of an aqueous mixture or solution.
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2. The method of claim 1, wherein the first citrate-
presenting composition promotes osteoblast phenotype pro-
gression in the population of bonecells.
3. The methodofclaim 1, wherein the bonecells comprise
bone stem cells.
4. The method of claim 1, wherein the bone cells are in
vitro.
5. The method of claim 1, wherein the first citrate-
presenting composition comprises citric acid or aqueous
citrate.
6. The method of claim 1 further comprising releasing
citrate from the polymer or oligomer by degrading the
polymer or oligomer.
7. The methodofclaim 6, wherein degrading the polymer
or oligomer comprises hydrolyzing an ester bond of the
polymer or oligomer.
8. The method of claim 1, wherein the first citrate-
presenting composition comprises a polymer or oligomer
having the structure of Formula (1):
@oO. OR, oO OR,
H H
R,O O. 0. Oo oO Oo N. N
O OR, O O OR, O O
oO. OR, oO. OR,
R,O O. 0. O. 0. Oo
O OR; O O OR; O
40
45
wherein
R, is —H, —OC(O)NHYVunr, or VU ;y
yvyVY represents an additional chain of repeating
units having the structure of Formula (1); and
m, n, and p are 8; and
q is 6.
9. The method of claim 1, wherein the first citrate-
presenting composition comprises a polymer or oligomer
having the structure of Formula (II):
qq)oO. OR, 0. OR2
Oo oO ORg,R,OyywySO
n P
i
Oo OR Oo 0 OR, 0
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wherein wherein the first polymer or oligomer is blended with the
R, is —H or vw ; second polymeror oligomer.
yvyVY represents an additional chain of repeating 11. The method of claim 10, wherein the first polymer or
units having the structure of Formula (II); and oligomer and the second polymer or oligomer are cross
m, n, and p are 8. 5 linked with one another to form a polymer network.
10. The method of claim 1, wherein the first citrate- 12. The method of claim 11 further comprising a particu-
presenting composition comprises: late material dispersed in the polymer network, the particu-
a first polymer or oligomer having the structure of For- late material comprising one or more of hydroxyapatite,
mula (I) tricalcium phosphate, biphasic calcium phosphate, bioglass,
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wherein ceramic, magnesium powder, magnesium alloy, and decel-
R, is —H, —OC(O)NHyw, or WU ; 45 lularized bone tissue particles.
yVVUW represents an additional chain of repeating
units having the structure of Formula (1); and 13. The method of claim 1 further comprising providing
m, n, and p are 8; and a biological factor to the bonecells.
q is 6; and
a second polymer or oligomer having the structure of 50 14. The method of claim 13, wherein the biological factor
Formula (II): comprises BMP-2.
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wherein 15. The method of claim 1, wherein the first citrate-
R, is —H or vu; presenting composition and the second citrate-presenting
yvyVY represents an additional chain of repeating 65 composition have the same composition.
units having the structure of Formula (II); and
m, n, and p are 8, ek oe kk
